药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Pirbuterol
Ribociclib
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ribociclib.
Pirbuterol
Ivabradine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ivabradine.
Pirbuterol
Asenapine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Asenapine.
Pirbuterol
Temafloxacin
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Temafloxacin.
Pirbuterol
Dexverapamil
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dexverapamil.
Pirbuterol
Penfluridol
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Penfluridol.
Pirbuterol
Lorcainide
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Lorcainide.
Pirbuterol
Bunaftine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Bunaftine.
Pirbuterol
Nizofenone
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Nizofenone.
Pirbuterol
Sultopride
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Sultopride.
Pirbuterol
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Sitafloxacin.
Pirbuterol
Oxatomide
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxatomide.
Pirbuterol
Abexinostat
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Abexinostat.
Pirbuterol
Mizolastine
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Mizolastine.
Pirbuterol
Ricolinostat
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Ricolinostat.
Pirbuterol
Simendan
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Simendan.
Pirbuterol
CUDC-101
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with CUDC-101.
Pirbuterol
Gilteritinib
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Gilteritinib.
Pirbuterol
Entinostat
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Entinostat.
Pirbuterol
Mocetinostat
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Mocetinostat.